CoChat

Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions

den Hollander, Wouter J, Holster, I Lisanne, den Hoed, Caroline M, Capelle, Lisette G, Tang, Tjon J, Anten, Marie-Paule, Prytz-Berset, Ingrid, Witteman, Ellen M, ter Borg, Frank, Hartog, Gijsbert den, Bruno, Marco J, Peppelenbosch, Maikel Petrus, Lesterhuis, Wilco, Doukas, Michael, Kuipers, Ernst J, Spaander, Manon C W · 2019 · Gut
Cited by 158

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Objective: International guidelines recommend endoscopic surveillance of premalignant gastric lesions. However, the diagnostic yield and preventive effect require further study. We therefore aimed to assess the incidence of neoplastic progression and to assess the ability of various tests to identify patients most at risk for progression. Design: Patients from the Netherlands and Norway with a previous diagnosis of atrophic gastritis (AG), intestinal metaplasia (IM) or dysplasia were offered endoscopic surveillance. All histological specimens were assessed according to the updated Sydney classification and the operative link on gastric intestinal metaplasia (OLGIM) system. In addition, we measured serum pepsinogens (PG) and gastrin-17. Results: 279 (mean age 57.9 years, SD 11.4, male/female 137/142) patients were included and underwent at least one surveillance endoscopy during follow-up. The mean follow-up time was 57 months (SD 36). Four subjects (1.4%) were diagnosed with high-grade adenoma/dysplasia or invasive neoplasia (ie, gastric cancer) during follow-up. Two of these patients were successfully treated with endoscopic submucosal dissection, while the other two underwent a total gastrectomy. Compared with patients with extended AG/IM (PGI/II≤3 and/or OGLIM stage III–IV), patients with limited AG/IM (PG I/II>3 and OLGIM stage 0–II) did not develop high-grade adenoma/dysplasia or invasive neoplasia during follow-up (p=0.02). Conclusion: In a low gastric cancer incidence area, a surveillance programme can detect gastric cancer at an early curable stage with an overall risk of neoplastic progression of 0.3% per year. Use of serological markers in endoscopic surveillance programmes may improve risk stratification.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2017-314498

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 158

Metadata

Authors
den Hollander, W. J., Holster, I. L., den Hoed, C. M., Capelle, L. G., Tang, T. J., Anten, M.-P., Prytz-Berset, I., Witteman, E. M., ter Borg, F., Hartog, G. D., Bruno, M. J., Peppelenbosch, M. P., Lesterhuis, W., Doukas, M., Kuipers, E. J., & Spaander, M. C. W.
Venue
Gut
Publisher
BMJ
Published
2018-06-06
Volume
68
Issue
4
Pages
585-593
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2805313569
Cited by
158
References
6
FWCI
16.73
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions. https://app.cochat.ai/papers/10.1136/gutjnl-2017-314498
The paper
den Hollander, W. J., Holster, I. L., den Hoed, C. M., Capelle, L. G., Tang, T. J., Anten, M.-P., Prytz-Berset, I., Witteman, E. M., ter Borg, F., Hartog, G. D., Bruno, M. J., Peppelenbosch, M. P., Lesterhuis, W., Doukas, M., Kuipers, E. J., & Spaander, M. C. W. (2019). Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions. Gut. https://doi.org/10.1136/gutjnl-2017-314498

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.